Results of a Large Phase 2 siRNA Study: Target Expression Translates to Therapeutic Outcomes
Results of large (N=326) P2 study showed QPI-1002, a systemically administered siRNA targeting p53, significantly reduced the clinical endpoint of severity of delayed graft function post-transplant, especially in kidneys from older donors (p<0.016); which are known to have increased p53. A P3 study is planned based on these significant results.
Elizabeth C. Squiers, M.D., Deputy Chief Medical Officer, VP, Pharmcovigilance, Quark Pharmaceuticals, Inc.